key: cord-1008037-1gu6254w
authors: Yadav, Pragya D.; Nyayanit, Dimpal A.; Gupta, Nivedita; Shastri, Jayanthi; Sahay, Rima R.; Patil, Deepak Y.; M. Shete, Anita; Razdan, Alpana; Agrawal, Sachee; Kumar, Abhinendra; Majumdar, Triparna; Patil, Savita; Sarkale, Prasad; Baradkar, Shreekant; Dudhmal, Manisha; Kaur, Harmanmeet; Aggarwal, Neeraj
title: Detection and isolation of SARS‐CoV‐2 Eta variant from the international travelers and local residents of India
date: 2022-03-07
journal: J Med Virol
DOI: 10.1002/jmv.27676
sha: 740204b5830cd579f035a675d0cb8864931812dc
doc_id: 1008037
cord_uid: 1gu6254w

International travel has been the major source for the rapid spread of new SARS‐CoV‐2 variants across the globe. During SARS‐CoV‐2 genomic surveillance, a total of 212 SARS‐CoV‐2 positive clinical specimens were sequenced using next‐generation sequencing. A complete SARS‐CoV‐2 genome could be retrieved from 90 clinical specimens. Of them, 14 sequences belonged to the Eta variant from clinical specimens of international travelers (n = 12) and local residents (n = 2) of India, and 76 belonged to other SARS‐CoV‐2 variants. Of all the Eta‐positive specimens, the virus isolates were obtained from the clinical specimens of six international travelers. Many variants of interest have been found to cause substantial community transmission or cluster infections. The detection of this variant with lethal E484K mutation across the globe and India necessitates persistent genomic surveillance of the SARS‐CoV‐2 variants, which would aid in taking preventive action.

With ongoing genomic surveillance of SARS-CoV-2 across the globe, more than 6,694,501 complete genome sequences have been generated till January 3, 2022. 1 Such extensive surveillance has helped in the timely identification of various SARS-CoV-2 variants. The first variant with D614G mutation in spike protein was identified in early 2020 which later became the dominant strain worldwide. 2 health events have been reported related to these variants. [2] [3] [4] Some of these variants were reported to be capable of higher transmission while the others could reduce the neutralization capabilities of the currently available vaccines. [2] [3] [4] The World Health Organization (WHO) has classified the new variants other than VOC under the VOI category which includes the variants of which few are likely to pose a public health threat. 3 Many of them are found to cause substantial community transmission or cluster infections.

Of these, the Eta variant has grabbed special attention within the predominance over other variants of concern. As per WHO, the Eta variant is different from all other variants because it carries both E484K and F888L mutations. The E484K has also been found in the gamma, zeta, and beta variants which are variants of concern. 3,4 The variant was initially reported for the first time from the UK and Nigeria during December 2020. Since then, the Eta variant has marked its presence in 85 countries with around 9176 sequences have been reported around the world, with a cumulative prevalence of <0.5% till incubator at 37°C and observed daily for CPEs under an inverted microscope (Nikon). Cellular morphological changes were recorded using a camera (Nikon). 8 Figure 1 depicts the neighbor-joining tree for the retrieved SARS-CoV-2 sequences (>98%) and the reference sequences. 

The spike of concern-the novel variants of SARS-CoV-2

World Health Organization (WHO)

European Centre for Disease Prevention and Control (ECDC)

1.525 lineage report

SARS-CoV-2 variants of concern and variants under investigation in England Technical briefing 7

Complete genome sequencing of Kaisodi virus isolated from ticks in India belonging to phlebovirus genus, family phenuiviridae

First isolation of SARS-CoV-2 from clinical samples in India

Post-vaccination COVID-19: a case-control study and genomic analysis of 119 breakthrough infections in partially vaccinated individuals

BNT162b2-elicited neutralization of B. 1.617 and other SARS-CoV-2 variants

Detection and isolation of SARS-CoV-2 Eta variant from the international travelers and local residents of India

The authors gratefully acknowledge the support extended by Prof. 

The authors declare no conflicts of interest.

The study was approved by the Institutional Biosafety Committee 

All data from the study were made available in the study.

http://orcid.org/0000-0002-0861-7166Neeraj Aggarwal http://orcid.org/0000-0003-3139-2994